Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).

Robert L. Ferris,Yael Flamand,Gregory S. Weinstein,Shuli Li,Harry Quon,Ranee Mehra,Joaquín J. García,Jolie Ringash,Jan S. Lewin,Umamaheswar Duvvuri,Bert W. OMalley,Enver Ozer,Giovana R. Thomas,Wayne M. Koch,Michael E. Kupferman,Richard Bell,Nabil F. Saba,Miriam N. Lango,Lynne I. Wagner,Barbara Burtness

Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).

2021

6010Background: Definitive or postoperative chemoradiation (CRT) is highly curative for human papillomavirus-associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a potenti...

Keywords:

Surgery
surgical resection
locally advanced
low dose
Cancer
Medicine
Randomized controlled trial
Toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations